Camazepam

Structural formula
General
Non-proprietary name	Camazepam
other names	7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1 H -1,4-benzodiazepin-3-yl- ( N , N -dimethyl) carbamic acid ester
Molecular formula	C 19 H 18 CIN 3 O 3
Brief description	White, krist. Powder, odorless in its pure state
External identifiers / databases
EC number	252-866-6
ECHA InfoCard	100.048.046
PubChem	37367
ChemSpider	34285
DrugBank	DB01489
Wikidata	Q3651150
Drug information
ATC code	N05 BA15
Drug class	Benzodiazepine; Anxiolytic;
properties
Molar mass	371.8 g · mol -1
Physical state	firmly
Melting point	173-174 ° C
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
H and P phrases	H: 225-302 + 312 + 332-319
	P: 210-233-240-241-242-243-261-264-270-280-301 + 312 + 330-303 + 361 + 353-304 + 340 + 312-305 + 351 + 338-363-501
Toxicological data	970 mg kg −1 ( LD 50 , mouse , oral ) ; 4 gm kg −1 ( LD 50 , rat , oral ) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Camazepam is a drug from the benzodiazepine group and has amnestic , anxiolytic , anticonvulsant , hypnotic , sedative and muscle-relaxing potential. The anxiolytic properties are particularly pronounced, which is why it is used in medicine as an anxiolytic .

Camazepam was launched in 1978 by Boehringer Ingelheim under the finished drug name Albego . It is no longer available in stores today.

Pharmacokinetics

Camazepam is the dimethyl carbamate ester of temazepam , which in turn is the metabolite of diazepam . Over 10 different metabolites are formed, including temazepam, oxazepam and hydroxycamazepam. The bioavailability is relatively high at 90% and the dose equivalent to 10 mg diazepam is 20 mg. The half-life is believed to be between 6.4 and 10.5 hours. A small study on 25 patients has shown that the anxiolytic effect of camazepam is superior to that of diazepam.

Side effects

Common side effects are drowsiness, dizziness, headache, drowsiness, and confusion. In rare cases, a paradoxical (opposing) effect with excitement (fear, aggressiveness, agitated state of confusion) can occur, which must never be answered by increasing the dose. Camazepam, like all drugs from the benzodiazepine class, has a high potential for dependence and abuse.

Trade names

Monopreparations

Albego (D, IT, CH, ES, all no longer in trade), Limpidon (IT, also out of trade)

Individual evidence

^ Fv Bruchhausen, S. Ebel, AW Frahm, E. Hackenthal: Hager's handbook of pharmaceutical practice substances AD . Springer-Verlag, 2013, ISBN 978-3-642-57995-0 , pp. 643 ( limited preview in Google Book search).
↑ Patent US3799920 : 1,4-BENZODIAZEPINE DERIVATIVES. Published October 29, 1974 , Inventors: G. Ferrari, C. Casagrande. ‌
↑ ^a ^b Safety Data Sheet. (PDF) In: cerilliant.com. Cerilliant, accessed March 30, 2019 .
↑ ^a ^b M Cesa-Bianchi, P Ghirardi, F Ravaccia: A preliminary double-blind study with SB 5833 (camazepam), a new benzodiazepine derivative. . In: drug research. Drug Research . 24, No. 12, 1974, p. 2032. PMID 4156178 .
↑ DE Patent 2142181A1
^ G Tallone, P Ghirardi, MC Bianchi: Reaction time to acoustic or visual stimuli after administration of camazepam and diazepam in man. . In: drug research 30 . 30, No. 6, 1980, pp. 1021-1024. PMID 6106497 .
↑ Guthy H .: The medicinal treatment of anxiety in alcoholism in the withdrawal stage . In: MMW, Munchener Medizinische Wochenschrift . 117, No. 35, 1975, p. 1390. PMID 241014 .
^ William Andrew Publishing (Ed.): Pharmaceutical Manufacturing Encyclopedia . Elsevier, 2013, ISBN 978-0-8155-1856-3 ( limited preview in Google Book Search).
↑ A Morino, A Nakamura, K Nakanishi, N Tatewaki, M Sugiyama: Species differences in the disposition and metabolism of camazepam. . In: Xenobiotica . 15, No. 12, 1985, pp. 1033-1043. PMID 2868575 .
↑ Lutz G. Schmidt (Ed.): Evidenzbasierte Suchtmedizin . Chapter 7, 7.1 Hypnotics / Sedatives. Deutscher Ärzteverlag, 2006, ISBN 978-3-7691-0520-9 ( limited preview in the Google book search).
↑ Legheand J, Cuisinaud G, Bernard N, Riotte M, Sassard J .: Pharmacokinetics of intravenous camazepam in dogs. . In: drug research . 32, No. 7, 1982, pp. 752-756. PMID 6127087 .
↑ R Deberdt: camazepam versus diazepam: a double blind trial on psychoneurotic patients . In: Current Therapeutic Research . 17, No. 1, 1975, pp. 32-39. PMID 237742 .

[F.v._Bruchhausen,_S._Ebel,_A.W._Frahm,_E._Hackenthal-1] Fv Bruchhausen, S. Ebel, AW Frahm, E. Hackenthal: Hager's handbook of pharmaceutical practice substances AD . Springer-Verlag, 2013, ISBN 978-3-642-57995-0 , pp. 643 ( limited preview in Google Book search).

[2] Patent US3799920 : 1,4-BENZODIAZEPINE DERIVATIVES. Published October 29, 1974 , Inventors: G. Ferrari, C. Casagrande. ‌

[MSDS-3] Safety Data Sheet. (PDF) In: cerilliant.com. Cerilliant, accessed March 30, 2019 .

[ToxDaten-4] M Cesa-Bianchi, P Ghirardi, F Ravaccia: A preliminary double-blind study with SB 5833 (camazepam), a new benzodiazepine derivative. . In: drug research. Drug Research . 24, No. 12, 1974, p. 2032. PMID 4156178 .

[5] DE Patent 2142181A1

[6] G Tallone, P Ghirardi, MC Bianchi: Reaction time to acoustic or visual stimuli after administration of camazepam and diazepam in man. . In: drug research 30 . 30, No. 6, 1980, pp. 1021-1024. PMID 6106497 .

[7] Guthy H .: The medicinal treatment of anxiety in alcoholism in the withdrawal stage . In: MMW, Munchener Medizinische Wochenschrift . 117, No. 35, 1975, p. 1390. PMID 241014 .

[Markteinführung-8] William Andrew Publishing (Ed.): Pharmaceutical Manufacturing Encyclopedia . Elsevier, 2013, ISBN 978-0-8155-1856-3 ( limited preview in Google Book Search).

[9] A Morino, A Nakamura, K Nakanishi, N Tatewaki, M Sugiyama: Species differences in the disposition and metabolism of camazepam. . In: Xenobiotica . 15, No. 12, 1985, pp. 1033-1043. PMID 2868575 .

[Äquivalenzdosis-10] Lutz G. Schmidt (Ed.): Evidenzbasierte Suchtmedizin . Chapter 7, 7.1 Hypnotics / Sedatives. Deutscher Ärzteverlag, 2006, ISBN 978-3-7691-0520-9 ( limited preview in the Google book search).

[11] Legheand J, Cuisinaud G, Bernard N, Riotte M, Sassard J .: Pharmacokinetics of intravenous camazepam in dogs. . In: drug research . 32, No. 7, 1982, pp. 752-756. PMID 6127087 .

[12] R Deberdt: camazepam versus diazepam: a double blind trial on psychoneurotic patients . In: Current Therapeutic Research . 17, No. 1, 1975, pp. 32-39. PMID 237742 .